Case Report: Early T-cell precursor acute lymphoblastic leukemia with aberrant CD19 expression and an

Yan Lu, Yiran Chen, Qiaohong Zhang, Gongqiang Wu

Abstract readCase Reports

In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yan Lu *Clinical Laboratory, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, China.

Yiran Chen *School of Medicine, Hangzhou City University, Hangzhou, China.

Qiaohong ZhangClinical Laboratory, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, China.

Gongqiang WuThe Department of Hematology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a high-risk subtype of T-cell acute lymphoblastic leukemia (T-ALL). Aberrant CD19 expression in ETP-ALL may lead to misdiagnosis of mixed-phenotype acute leukemia. Notably, Case report: We present the case of a 29-year-old male with progressive right retroauricular and cervical lymphadenopathies complicated by severe febrile neutropenia and polymicrobial sepsis. Peripheral blood testing revealed 80% blasts. Bone marrow flow cytometry demonstrated blasts strongly positive for cytoplasmic CD3 and CD7, with aberrant CD19 expression and co-expression of CD34, CD33, and dim cytoplasmic CD79a. The blasts showed dim CD5 expression but were negative for CD1a, CD8, CD10, CD22, and myeloperoxidase, consistent with an ETP-ALL immunophenotype. Next-generation sequencing identified Conclusion: To our knowledge, this case represents the first reported ETP-ALL with an

Indexed as

ETP−ALLflow cytometryFLT3−ITDnext−generation sequencingNPM1 mutation

Identifiers

PMID42558452

DOI10.3389/fonc.2026.1890324

PMCPMC13437464

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.